MAPT and Alzheimer disease: In the case of AD, there is some evidence that PTA performance may be associated with biomarkers amyloid-beta and phosphorylated tau on brain PET [29] in cognitively healthy older adults, while subjectively reported hearing impairment was found to correlate with total CSF tau and phosphorylated tau levels in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Chinese Alzheimer’s Biomarker and Lifestyle (CABLE) multi-centre cohort studies [26].